Supreme Court’s Directive on Zydus’ Breast Cancer Biosimilar Sparks Industry Concerns

Sub : Sci

Sec: Health

Why in News

The legal case involving Zydus Life sciences’ biosimilar drug Sigrima, a generic version of Roche’s breast cancer treatment Pertuzumab, has taken a new direction following a Supreme Court decision. The case raises important concerns for the pharmaceutical industry, particularly regarding patent rights and the future of biosimilar drugs.

What are Biosimilars?

Biosimilars are biologic medicines designed to be highly similar to an already approved biologic drug, known as the reference product. These medicines are used to treat a range of conditions, offering alternative options to existing biologics.
Biosimilars are nearly identical to their reference drugs in terms of safety, purity, and potency.
They might have slight variations in inactive components that do not affect clinical outcomes.
Biosimilars are not new medications; they are modelled after existing biologics that have already been thoroughly tested and widely prescribed.
Some well-known reference biologics include etanercept, infliximab, and adalimumab.
The production of biosimilars begins with the same amino acid base as the reference product.
Manufacturing follows a stringent, step-by-step process, ensuring the biosimilar maintains high similarity to the reference drug.
Like the reference products, biosimilars are derived from biological sources, differentiating them from chemically synthesized drugs.
All biosimilars are classified as prescription drugs, requiring medical oversight for their use.

Biosimilars vs. Generic Drugs

While biosimilars and generic drugs serve a similar purpose of providing more affordable alternatives, they differ significantly:
Generics are exact chemical copies of brand-name drugs.
Biosimilars, due to their biological complexity, are not identical but are designed to be highly similar to the original biologic. This is why biosimilars undergo rigorous comparison studies before approval.
Regulation and Approval: To gain approval as a biosimilar, the drug must demonstrate that it is highly similar to the reference biologic in laboratory and clinical settings.
Differences are only allowed if they do not impact the clinical effectiveness or safety of the biosimilar.